Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA (XRAY) reported an insider transaction by its EVP & CFO. On 10/10/2025, the officer acquired 556.226 shares (Transaction Code A) at $0. A footnote explains these represent dividend equivalents on previously granted RSUs, issued as additional RSUs that vest on the same schedule as the underlying awards and convert to common stock on a 1:1 basis.
After this transaction, the reporting person beneficially owned 44,011.347 shares, held directly.
DENTSPLY SIRONA (XRAY) director Brian T. Gladden reported an automatic credit of 286.094 additional RSUs on 10/10/2025 at $0, reflecting dividend equivalents on prior RSU awards. Each RSU converts 1:1 into common stock and follows the same vesting schedule as the underlying awards. After this entry, his beneficial ownership stood at 28,726.563 shares, held directly.
DENTSPLY SIRONA (XRAY) reported an insider equity change by director Betsy D. Holden. On 10/10/2025, the filing lists Common Stock acquired under code “A” totaling 646.937 at $0. The footnote explains these reflect dividend equivalents on restricted stock units (RSUs) credited as additional RSUs, which vest on the same schedule as the underlying awards, and each RSU converts to common stock on a 1:1 basis. Following the transaction, Holden beneficially owned 53,902.896 shares, held directly.
DENTSPLY SIRONA (XRAY) director filed a Form 4 reporting RSU dividend equivalents. On 10/10/2025, the reporting person acquired 286.094 restricted stock units as dividends on existing RSUs at a price of $0. Following this transaction, beneficial ownership stands at 40,897.4765 shares, held directly.
The company states these are dividends on RSUs awarded to the reporting person, delivered as additional RSUs that carry the same vesting terms as the underlying awards. Each RSU converts to common stock on a 1:1 basis, and the dividend RSUs vest simultaneously with the related RSUs.
DENTSPLY SIRONA (XRAY): Form 4 insider transaction by a director. On 10/10/2025, 310.397 shares of common stock were acquired at $0 as dividends on restricted stock units credited to a Family Partnership. Following this, beneficial holdings were 24,357.397 shares indirect by Family Partnership, 82,301.434 shares direct, and 21,000 shares indirect by a Gregory Lucier IRA.
On 10/14/2025, the reporting person made a gift (Code G) of 17,200 non‑qualified stock options with a $12.96 exercise price to a Family Partnership. These options are exercisable beginning 08/08/2026 and expire on 08/08/2035. The filing notes the gift and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
DENTSPLY SIRONA (XRAY) director reported routine equity accruals. On 10/10/2025, the reporting person acquired 359.576 shares of common stock at $0 as dividend equivalents on previously granted RSUs. Following this transaction, directly held common stock totaled 28,451.376 shares.
The filing also shows an acquisition of 123.3618 units of phantom stock under the Directors' Deferred Compensation plan at a derivative price of $11.98. Phantom stock represents the economic equivalent of common stock and becomes payable in shares upon the director’s termination of service. After this accrual, the director held 11,743.5642 phantom stock units.
Notes clarify these were dividend-related accruals for RSUs and phantom stock, with RSUs converting to common stock on a 1:1 basis and phantom stock payable in common stock upon termination.
DENTSPLY SIRONA (XRAY) director reported an equity accrual. On 10/10/2025, the reporting person acquired 179.449 units at $0, reflecting dividends credited on previously awarded RSUs that carry the same vesting terms. Each RSU converts to common stock on a 1:1 basis.
Following this transaction, beneficial ownership stood at 48,005.925 on a direct basis. These credits represent routine dividend equivalents tied to outstanding RSUs rather than open‑market purchases.
DENTSPLY SIRONA (XRAY) reported insider equity accruals. Officer Richard C. Rosenzweig received 766.323 shares of common stock on 10/10/2025 at $0 (code A) from dividends on previously awarded RSUs that vest with the underlying awards. Following the transaction, directly held common stock was 85,183.54 shares.
He also acquired 80.9848 shares of phantom stock under the Supplemental Executive Retirement Plan at a derivative price of $11.98, bringing directly held phantom units to 6,142.9981. Each RSU and phantom unit is equivalent to one share of common stock, with phantom stock payable upon termination of employment.
DENTSPLY SIRONA (XRAY) reported a routine insider update: Director Janet S. Vergis acquired 179.449 additional common shares on 10/10/2025, recorded at $0, from dividend equivalents on previously granted restricted stock units (RSUs). The acquisition is coded “A.”
Following the transaction, her beneficial ownership stands at 44,300.167 common shares, held directly. The filing notes these credits reflect RSU dividend equivalents that vest on the same schedule as the related RSUs, with each RSU converting to one share.
DENTSPLY SIRONA announced that the SEC’s Division of Enforcement has concluded its investigation and does not intend to recommend any enforcement action against the company. The inquiry, initiated by the SEC in connection with an internal review led by the Audit and Finance Committee into certain financial reporting matters raised by employees, began in May 2022 and closed on October 14, 2025. The company had voluntarily contacted the SEC and fully cooperated throughout.
The closure removes a regulatory overhang tied to past financial reporting questions and reflects the regulator’s decision not to pursue action. Management characterized the outcome as a significant and favorable development.